Novo Nordisk Charts Signal Weakness Amid Wegovy Warning, Expert Says 'Could've Played Out VERY Differently If They Had Embraced $HIMS'

How will new US tariffs affect EU exports? Why did Apple’s profits soar despite tariff costs? What impact will Trump’s tariffs have on Canada? How is Amazon managing tariff-related cost pressures? Why is Microsoft’s market value hitting $4 trillion? How did Figma’s IPO triple its stock price? What’s behind Reddit’s surge in revenue and stock?

Novo Nordisk Charts Signal Weakness Amid Wegovy Warning, Expert Says 'Could've Played Out VERY Differently If They Had Embraced $HIMS'

benzinga.com/markets/equities/25/07/46716995/novo-nordisk-charts-signal-weakness-amid-wegovy-warning-expert-says-couldve-played-out-very-diff

Weight-loss drugmaker Novo Nordisk A/S (NYSE:NVO)’s technical chart is displaying a largely bearish trend amid a profit warning issued by the company tied to its blockbuster obesity drug Wegovy. However, this expert believes that the Danish pharmaceutical giant could have avoided some…

This story appeared on benzinga.com, 2025-07-30 11:06:32.